2. Academic Validation
  3. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

  • Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. doi: 10.1080/13543784.2022.2042252.
Alessandro Rizzo 1,  Antonio Cusmai 1,  Silvana Acquafredda 1,  Lucia Rinaldi 1,  Gennaro Palmiotti 1
Affiliations

Affiliation

  • 1 Struttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S, Istituto Tumori "Giovanni Paolo Ii", Bari, Italy.
PMID: 35171746 DOI: 10.1080/13543784.2022.2042252
Keywords

Breast cancer; antibody drug conjugate; combinations; ladiratuzumab vedotin; sacituzumab govitecan; triple negative breast cancer.

Figures
Products